SPRY

ARS Pharmaceuticals' stock price has experienced significant volatility in the past six months, with a decline of 60.4% over the past 12 months. On June 24, 2026, the stock fell over 23% after the company disclosed that neffy received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle, contrary to previous management projections, leading to an investigation into potential securities law violations. On May 15, 2026, the company reported Q1 2026 financial results with total revenue of $22.7 million, a 184% increase from Q1 2025, driven by $17.5 million in U.S. net product revenue from neffy sales, but reported a net loss of $60.6 million, resulting in a -6.49% stock change. On August 13, 2026, ARS Pharmaceuticals outlined strategic priorities and reported Q2 2026 financial results, with total revenue of $33.7 million and U.S. net product revenue reaching $26.2 million, but posted a net loss of $62.3 million, missing EPS expectations, leading to a -7.38% stock change. In September 2026, several insider stock sales were reported, including officers Eric Karas and Richard Lowenthal proposing to sell shares.